Definitive Contract 75A50123C00040
Award Date
8/28/23
Potential Completion Date
8/27/26
Potential Value
$7.3M
Awardee
Amgen Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Cost Sharing
Place of Performance
Thousand Oaks, CA 91320, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $999,406,548.42 firm fixed price definitive contract awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Amgen USA Inc., a leading biotechnology company. The contract is for the treatment of thrombocytopenia or platelet loss in a mass casualty event, with the procured therapeutic to be delivered to the Strategic National Stockpile as vendor managed inventory. The contract exercises option periods 3 for...
This federal contract award was granted by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,515.52 delivery order contract is for the supply of NPLATE 125 MCG VIALS, a specialized pharmaceutical product. The contract has a firm fixed price pricing type and an ultimate completion date of January 28, 2025. The award is associated with a larger Indefinite Delivery Contract (IDC) between...
This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,375.84 firm fixed-price contract is for the delivery of NPLATE 125 MCG VIALS, a specialty medication. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical. This IDC serves as a primary vehicle for...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of NPLATE 125 MCG VIALS. The contract has a ceiling value of $4,604.88 and a completion date of December 30, 2024. It is a firm fixed-price contract with no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of pharmaceutical product NPLATE 125 MCG VIALS to the Defense Logistics Agency (DLA), a defense agency. The contract is a Delivery Order with a Firm Fixed Price of $2,225.49 and a completion date of July 24, 2024. Amerisourcebergen is a major supplier of pharmaceuticals and medical supplies to the U.S. federal government, particularly the Department of Defense (DoD) and Veterans Affairs...
This federal contract award, with a value of $4,450.98, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp. The contract is for the delivery of 125 mcg vials of the drug Nplate, with a performance period through November 14, 2024. The contract type is a Delivery Order with Firm Fixed Pricing. This contract award is not designated with any set-aside requirements, indicating open competition. Amerisourcebergen Drug Corp is a major pharmaceutical...
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Chrysalis Biotherapeutics, Inc. The contract is for "A NOVEL NUCLEAR COUNTERMEASURE TARGETING ENDOTHELIAL CELLS AND STEM CELLSTO COMBAT ARS AND DELAYED MULTIPLE ORGAN DYSFUNCTION" and has a ceiling value of $6,954,508.60. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type and has an ultimate completion date of August 31, 2021. The...
This is a federal contract award to Partner Therapeutics, Inc., a biopharmaceutical company based in Lexington, Massachusetts, to provide a colony stimulating factor (G-CSF or GM-CSF) as a medical countermeasure for treating neutropenia arising from exposure to ionizing radiation. The contract, awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR), has a ceiling value of $37,626,711.32 and an ultimate completion...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of 125 mcg vials of the drug Nplate. The contract has a ceiling value of $8,901.96 and has a period of performance through October 21, 2024. AmerisourceBergen Drug Corp is a major pharmaceutical distributor that holds several Indefinite Delivery Contracts (IDCs) with federal agencies, including a $999,999,999 IDC with DLA Troop Support Medical for a wide range of medical...
This is a $1,663,985.13 firm fixed-price delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer of goods. The contract supports the process development and cGMP compliant manufacture of a B19 parvovirus vaccine drug product for use in Phase I/II clinical trials. This contract is part of a larger...